Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Unaltered homocysteine levels during simvastatin therapy].

H Sinzinger1, F Chehne, P Schmid

  • 1Wilhelm Auerswald Atheroskleroseforschungsgruppe (ASF) Wien. Helmut.Sinzinger@akh-wien.ac.at

Wiener Klinische Wochenschrift
|August 23, 2000
PubMed
Summary

Simvastatin, a lipid-lowering drug, does not alter plasma homocysteine levels in patients with severe hypercholesterolemia. This study found no significant changes in homocysteine concentrations during simvastatin therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative (99m)Tc-MIBI, (99m)Tc-tetrofosmin and (99m)Tc-furifosmin uptake in human soft tissue sarcoma cell lines.

European journal of nuclear medicine·2014
Same author

[Imaging of early carotid artery atherosclerotic lesions with 111In-labeled polyelonalhuman IgG (HIG)].

Nuklearmedizin. Nuclear medicine·2006
Same author

(Iso) Prostaglandins in saliva indicate oxidation injury after radioiodine therapy.

Revista espanola de medicina nuclear·2004
Same author

Effect of giving up cigarette smoking and restarting in patients with clinically manifested atherosclerosis.

Prostaglandins, leukotrienes, and essential fatty acids·2002
Same author

Endothelial dysfunction, atherosclerosis and diabetes.

Acta medica Austriaca·2001
Same author

Isoprostane 8-epi-PGF2alpha is frequently increased in patients with muscle pain and/or CK-elevation after HMG-Co-enzyme-A-reductase inhibitor therapy.

Journal of clinical pharmacy and therapeutics·2001

Area of Science:

  • Cardiovascular Medicine
  • Clinical Pharmacology

Background:

  • Elevated homocysteine levels are a known risk factor for vascular disease.
  • Certain medications, including some lipid-lowering drugs, can increase plasma homocysteine.
  • Familial heterozygous hypercholesterolemia is a condition requiring lipid-lowering treatment.

Purpose of the Study:

  • To investigate the effect of simvastatin on plasma homocysteine levels.
  • To determine if simvastatin influences homocysteine concentrations in patients with severe hypercholesterolemia.

Main Methods:

  • A study involving 57 patients with severe familial heterozygous hypercholesterolemia.
  • Plasma homocysteine levels were measured before and after 1, 3, and 6 months of simvastatin therapy.
  • Analysis included comparisons based on sex, smoking status, and simvastatin dosage (20 mg vs. 40 mg).

Related Experiment Videos

Main Results:

  • Simvastatin therapy did not result in any significant change in plasma homocysteine levels.
  • Males exhibited higher homocysteine levels than females.
  • Smokers generally had higher homocysteine concentrations than non-smokers.
  • No difference was observed between patients receiving 20 mg or 40 mg of simvastatin.
  • No correlation was found between simvastatin's lipid-lowering effect and homocysteine levels.

Conclusions:

  • Simvastatin does not appear to affect plasma homocysteine levels.
  • This finding contrasts with other lipid-lowering agents that have been shown to increase homocysteine.
  • Simvastatin can be used in patients with hypercholesterolemia without concern for elevated homocysteine levels.